Option Care 是所有配药药房均获得 PCAB 认证的全美首家家庭输液公司。
By: Option Care
October 3, 2017
BANNOCKBURN, Ill., Oct. 3, 2017 — Option Care Enterprises, Inc., one of the leading providers of home and alternate treatment site infusion therapy services, is the first national home infusion company to achieve accreditation at each of its compounding pharmacies by the Pharmacy Compounding Accreditation Board (PCAB). This ensures they meet or exceed the most rigorous standards.
The accreditation verifies all Option Care cleanroom pharmacies — in which sterile compounding of intravenous (IV) medications for specific physician orders is performed — meet the highest-level standards, far and above what is required in most states. A service of Accreditation Commission for Health Care (ACHC), PCAB accreditation offers the most comprehensive compliance solution in the industry based on more than 40 sterile compounding standards in the U.S. Pharmacopeial Convention (USP) guidelines, or USP 797.
Option Care 虽然已经拥有授予符合监管要求和认证标准的医疗保健机构的更广泛 ACHC 认证，但还是为其配药药房寻求 PCAB 认证，因为其致力于通过不断改进质量来超越标准。
“PCAB accreditation of all of our compounding pharmacies provides an objective, external validation of our commitment to quality,” said Brenda Wright, Vice President of Clinical Services, Option Care. “Going above and beyond what is required is what we do. It’s how we approach our clinical services from the perspective of total quality management. This accreditation speaks to our pledge to drive continuous quality improvement and provide optimal outcomes for our patients.”
PCAB 认证的特点是由一位独立专家进行广泛的现场调查，以确保符合 USP 795 和 USP 797 定义的非无菌和无菌的药房配药过程。ACHC 指出，PCAB 认证与药房对持续合规的承诺相结合，显著降低了与配制药物相关的风险，并表明其满足行业最高质量和安全标准的承诺。
“We are thrilled that Option Care has chosen to leverage the breadth of pharmacy accreditation programs ACHC offers,” said José Domingos, CEO of ACHC. “This demonstrates a commitment to delivering quality care for patients.”
在获得 PCAB 认证之前，Option Care 刚刚以 100% 的企业满分获得了 URAC 专业药房认证，此外 Option Care 的三家专业药房中心荣获了卓越称号。
关于 ACHC
ACHC is a non-profit organization that has stood as a symbol of quality and excellence since 1986. ACHC is the provider’s choice for compliance solutions because of its personal Account Advisors, relevant and realistic standards, competitive pricing, and a friendly, consultative approach to accreditation. Beginning July 2014, PCAB became a service of ACHC, offering programs for non-sterile (ref. USP 795) and sterile (ref. USP 797) compounding services. PCAB assesses the compounding process based on a specific set of standards that concentrate on the quality and consistency of compounded medications while incorporating performance improvement and ongoing compliance requirements. PCAB Accreditation reflects an organization’s dedication and commitment to meeting standards that facilitate a higher level of performance and patient care. For more information on ACHC’s accreditation programs and educational resources, or to download ACHC accreditation standards, visit www.achc.org.
关于 Option Care
Option Care Enterprises, Inc. (Option Care) is one of the nation’s largest and most trusted providers of home and alternate treatment site infusion services. An industry leader, the company draws on nearly 40 years of clinical care experience to offer patient-centered therapy management. Option Care’s signature Home Infusion Plus services include the clinical management of infusion medicines, nursing support and care coordination. Option Care’s multidisciplinary team of more than 1,800 clinicians — including pharmacists, nurses and dietitians — are able to provide home infusion service coverage for nearly all patients across the United States needing treatment for complex and chronic conditions. Learn more at www.OptionCare.com.
You might also be interested in:
接受免疫球蛋白家庭输液的 Option Care 患者得益于更好的疗效、更低的成本
SAN ANTONIO — Option Care patients treated with immunoglobulin (IG) therapy at home with a high level of clinical oversight had better outcomes compared to others receiving the therapy according to a first-of-its-kind study presented at the American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting this week. The researchers, who evaluated data […]
Option Care 家庭输液血友病患者使用较少的第八因子，研究表明既节省了成本又不影响疗效
ORLANDO, FL, July 26, 2016 — Hemophilia patients can be managed with less factor VIII without affecting outcomes and saving significant costs, suggests a study being presented at the World Federation of Hemophilia 2016 World Congress meeting today in Orlando. The Option Care study included 77 hemophilia A patients receiving home infusion of factor VIII. […]